Company Category: Pharmaceuticals & Biotech

Clin­i­cal-stage bio­phar­ma­ceu­ti­cal com­pa­ny devel­op­ing cen­tral ner­vous sys­tem ther­a­pies, includ­ing samelisant for exces­sive day­time sleepi­ness in nar­colep­sy.

Glob­al bio­phar­ma­ceu­ti­cal com­pa­ny devel­op­ing and com­mer­cial­iz­ing med­i­cines across neu­ro­science, gas­troen­terol­o­gy, oncol­o­gy, plas­ma-derived ther­a­pies, vac­cines, and rare dis­eases.

A vir­tu­al sleep clin­ic pro­vid­ing per­son­al­ized, sci­ence-backed care for insom­nia and sleep apnea, includ­ing cog­ni­tive behav­ioral ther­a­py for insom­nia (CBT‑I).

An FDA-cleared pre­scrip­tion dig­i­tal treat­ment deliv­er­ing cog­ni­tive behav­ioral ther­a­py for insom­nia (CBT‑I) for adults with chron­ic insom­nia or insom­nia dis­or­der.

Devel­ops non-inva­sive neu­rostim­u­la­tion prod­ucts, includ­ing Mod­ius Sleep for the treat­ment of chron­ic insom­nia.

Bio­phar­ma­ceu­ti­cal com­pa­ny focused on ther­a­pies for rare neu­ro­log­i­cal dis­eases, with a foun­da­tion in sleep-wake dis­or­ders.

Bio­phar­ma­ceu­ti­cal com­pa­ny focused on ther­a­pies for rare neu­ro­log­i­cal dis­eases, with a foun­da­tion in sleep-wake dis­or­ders.

Bio­phar­ma­ceu­ti­cal com­pa­ny devel­op­ing and com­mer­cial­iz­ing med­i­cines in neu­ro­science and oncol­o­gy, includ­ing ther­a­pies for nar­colep­sy and exces­sive day­time sleepi­ness.

Clin­i­cal-stage phar­ma­ceu­ti­cal com­pa­ny devel­op­ing med­i­cines for seri­ous dis­eases, includ­ing orex­in-ago­nist pro­grams for sleep-wake dis­or­ders.

Bio­phar­ma­ceu­ti­cal com­pa­ny devel­op­ing and com­mer­cial­iz­ing ther­a­pies for cen­tral ner­vous sys­tem dis­or­ders, includ­ing nar­colep­sy and exces­sive day­time sleepi­ness.